Compare GEL & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GEL | STOK |
|---|---|---|
| Founded | 1996 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.0B |
| IPO Year | 1996 | 2019 |
| Metric | GEL | STOK |
|---|---|---|
| Price | $14.15 | $24.97 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 14 |
| Target Price | $18.00 | ★ $46.46 |
| AVG Volume (30 Days) | 219.3K | ★ 782.2K |
| Earning Date | 11-05-2026 | 10-29-2026 |
| Dividend Yield | ★ 5.75% | N/A |
| EPS Growth | N/A | ★ 92.73 |
| EPS | ★ 0.21 | N/A |
| Revenue | ★ $2,912,770,000.00 | $184,420,000.00 |
| Revenue This Year | $9.79 | N/A |
| Revenue Next Year | N/A | $39.98 |
| P/E Ratio | $66.14 | ★ N/A |
| Revenue Growth | 43.60 | ★ 404.50 |
| 52 Week Low | $13.55 | $20.32 |
| 52 Week High | $18.64 | $40.22 |
| Indicator | GEL | STOK |
|---|---|---|
| Relative Strength Index (RSI) | 43.72 | 45.36 |
| Support Level | $13.65 | $24.21 |
| Resistance Level | $14.61 | $33.61 |
| Average True Range (ATR) | 0.30 | 1.33 |
| MACD | 0.03 | 0.35 |
| Stochastic Oscillator | 40.70 | 56.19 |
Genesis Energy LP focuses on the midstream segment of the crude oil and natural gas industry. It offers various services to crude oil and natural gas producers, and industrial and commercial enterprises. The company's reportable segments are: Offshore pipeline transportation, Marine transportation, and Onshore transportation and services. Maximum revenue is generated from the Offshore pipeline transportation segment, which includes the transportation and processing of crude oil and natural gas in the Gulf of America. The Marine transportation segment provides waterborne transportation of petroleum products and crude oil throughout North America; and the Onshore transportation and services segment deals with crude oil logistics, sour gas processing, and sells sulfur byproducts.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.